Olanzapine induced neuroleptic malignant syndrome
Open Access
- 1 January 2013
- journal article
- case report
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (1) , 98-9
Abstract
An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case of NMS, offending agent was immediately withdrawn and prompt treatment with bromocriptine and levodopa produced a good recovery. The various features of the case are discussed in view of the potential mortality of the syndrome.Keywords
This publication has 4 references indexed in Scilit:
- Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patientsIndian Journal of Psychiatry, 2009
- Antipsychotiques atypiques et syndrome malin des neuroleptiques : brève revue de la littératureL'Encéphale, 2008
- Preventability and severity assessment in reporting adverse drug reactionsAmerican Journal of Health-System Pharmacy, 1992
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981